"Lyfgenia FDA Approval Sparks Competition in Sickle Cell Treatment Market"
TL;DR Summary
The FDA's approval of two gene therapies for sickle cell disease paves the way for competition between Bluebird Bio's Lyfgenia and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy. While Casgevy has the advantage of being a CRISPR-based therapy, some physicians and patients may prefer the lentiviral vector technology behind Lyfgenia, despite the added risk of blood cancer.
Topics:business#bluebird-bio#crispr-therapeutics#gene-therapy#healthcare#sickle-cell-disease#vertex-pharmaceuticals
- Despite FDA approval for Lyfgenia, Bluebird faces stiff competition STAT
- F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editing The New York Times
- Gene editing could be a game changer for patients with sickle cell disease CBS Mornings
- A Sickle Cell Breakthrough Is Here. Now the Hard Part. Bloomberg
- Access barriers loom in Minnesota for blockbuster sickle cell therapy Star Tribune
Reading Insights
Total Reads
1
Unique Readers
4
Time Saved
0 min
vs 1 min read
Condensed
59%
144 → 59 words
Want the full story? Read the original article
Read on STAT